Holen Sie sich die Stockscreener-App
10.31
1.62%
-0.17
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth - Simply Wall Street
Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history - Yahoo Finance Australia
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027 - Seeking Alpha
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history - Yahoo Finance UK
Century Therapeutics, Inc. (IPSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wells Fargo Initiates Design Therapeutics at Overweight With $26 Price Target - marketscreener.com
tm2619715-5_s1none30.1514628s - SEC.gov
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Australia
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Singapore
Solid Biosciences (Nasdaq:SLDB)Stock Analysis - Simply Wall Street
Seres Therapeutics (Nasdaq:MCRB)Stock Analysis - Simply Wall Street
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to S&P Biotechnology Select Industry Index - marketscreener.com
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com Australia
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com South Africa
Design Therapeutics at Cantor conference: biomarker push takes center stage - Investing.com
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com Canada
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com India
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com UK
DSGN: DT-216 achieved robust biomarker and clinical gains in FA, with pivotal data expected in Q1 2027 - TradingView
A biotech company's conference chat will be webcast live Sept. 9. - Stock Titan
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%Risk Parity Rebalance - vinanet.vn
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%Corrective Wave - careplusvn.com
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%Wide Range Bar - dars.gov.et
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%ETF NAV Deviation - dars.gov.et
Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - sahmcapital.com
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch - Yahoo Finance
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch - AOL.com
Design Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
DSGN Q2 2026 Earnings: Narrower-than-Expected Loss Lifts SharesFiscal Year Earnings - vinanet.vn
DSGN Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 3.06% Stock GainMid-Term Outlook - Vinanet
Design Therapeutics Stock Price Forecast. Should You Buy DSGN? - StockInvest.us
Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares - Stock Titan
Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake - Stock Titan
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Design Therapeutics, Inc. $DSGN Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co. - MarketBeat
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - finance.yahoo.com
DSGN Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplinePreliminary Results - vinanet.vn
Renaissance Technologies LLC Buys 121,100 Shares of Design Therapeutics, Inc. $DSGN - MarketBeat
Design Therapeutics (DSGN) Rises 1.47% as Gene Therapy Plays Draw AttentionRectangle Pattern - dars.gov.et
Design Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Design Therapeutics Q2 Net Loss Narrows - Moomoo
Design Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Design Therapeutics posts Q2 loss, updates clinical trials - Investing.com
Design Therapeutics Q2 Net Loss Narrows - marketscreener.com
Design Therapeutics (NASDAQ:DSGN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - marketbeat.com
5.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):